Cargando…

Biomarkers of therapeutic response with immune checkpoint inhibitors

Immune checkpoint inhibitors (ICPIs) have revolutionized the treatment paradigm of a wide range of malignancies with durable responses seen in even advanced, refractory cancers. Unfortunately, only a small proportion of patients with cancer derive meaningful benefit to ICPI therapy, and its use is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bindal, Poorva, Gray, Jhanelle E., Boyle, Theresa A., Florou, Vaia, Puri, Sonam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Cancer Immunotherapy: Recent Advances and Challenges
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267267/ https://www.ncbi.nlm.nih.gov/pubmed/34277840 http://dx.doi.org/10.21037/atm-20-6396

Ejemplares similares

Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction
por: Florou, Vaia, et al.
Publicado: (2021)

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2021)

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
por: Hatic, Haris, et al.
Publicado: (2021)

Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease
por: Alexander, Swetha, et al.
Publicado: (2021)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Cancer immunotherapy: recent advances and challenges
por: Swami, Umang, et al.
Publicado: (2021)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
por: Lu, Yu, et al.
Publicado: (2023)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

Immune checkpoint inhibitors in ovarian cancer: where do we stand?
por: Leary, Alexandra, et al.
Publicado: (2021)

CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges
por: Narkhede, Mayur, et al.
Publicado: (2021)

Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
por: Rytlewski, Jeff, et al.
Publicado: (2021)

The dark side of immunotherapy
por: Okwundu, Nwanneka, et al.
Publicado: (2021)

Current status of intralesional agents in treatment of malignant melanoma
por: Zawit, Misam, et al.
Publicado: (2021)

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
por: Zhou, Fei, et al.
Publicado: (2022)

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
por: Tinker, Anna V., et al.
Publicado: (2023)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
por: Qiu, Xin, et al.
Publicado: (2023)

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis
por: Durbin, Sienna M, et al.
Publicado: (2020)

Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
por: Khononov, Irina, et al.
Publicado: (2021)

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
por: Cautela, Jennifer, et al.
Publicado: (2020)

Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
por: Reid, Pankti, et al.
Publicado: (2021)

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
por: Coustal, Cyrille, et al.
Publicado: (2023)

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
por: Drobni, Zsofia Dora, et al.
Publicado: (2023)

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
por: Brown, Landon C, et al.
Publicado: (2022)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors
por: Kelleher, Thomas, et al.
Publicado: (2021)

Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis
por: Alexander, James L, et al.
Publicado: (2022)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
por: Chen, Xinru, et al.
Publicado: (2020)

Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
por: Cuzzubbo, Stefania, et al.
Publicado: (2020)

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
por: Sheng, Hailong, et al.
Publicado: (2020)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors
por: Ahmed, Murtaza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5m70rerr00r03htlo3g978mbq1